Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart shield? statin may guard against chemo damage

NCT ID NCT07668076

Disease control Sponsor: Damanhour University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether atorvastatin, a cholesterol-lowering drug, can protect the heart in breast cancer patients receiving doxorubicin-based chemotherapy. 44 women with newly diagnosed breast cancer took atorvastatin daily for 3 months alongside their chemo. Researchers measured heart stress markers in the blood to see if the drug reduced heart damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atorvastatin
What this could lead to
If it works, this could point toward a way to reduce heart damage from doxorubicin chemotherapy in breast cancer patients.
What could go wrong
This is a small, early-phase study with only 44 participants. Results may not apply to all patients, and the heart-protective effect may be minimal or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

44 people

The number who actually took part.

Started

Nov 2022

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women with newly diagnosed breast cancer and ≥ 18 years old. 2. Naive to chemotherapy. 3. Left ventricular ejection fraction (LVEF) \> 55%. Exclusion Criteria: 1. Concurrent administration of any other cholesterol-lowering therapy. 2. Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range) 3. Evidence of renal dysfunction (creatinine level more than three times the upper limit of the normal range). 4. Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle or liver disease. 5. Concurrent administration of potent CYP3A4-inhibitors. 6. Pregnancy or breast-feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm doxorubicin induced cardiomyopathy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Doxorubicin induced cardiomyopathy

Contacts and locations

Locations

  • Damanhour university

    Beheira, Damanhour, 22511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.